Other
CN
EU
USA
Description: Devimistat (formerly also known as CPI613; CPI 613; CPI-613), a synthetic lipoate analog, is a novel and potent inhibitor of pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase with potential chemopreventive and antineoplastic activities. It disrupts mitochondrial metabolism and shows strong antitumor activity. Devimistat inhibits mitochondrial enzymes pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase in NCI-H460 cell line, it disrupts tumor cell mitochondrial metabolism. CPI-613 is developed to target the pyruvate dehydrogenase complex which is a key mitochondrial enzyme of anaerobic glycolysis in tumor cells.
References: J Mol Med (Berl). 2011 Nov;89(11):1137-48.
Related CAS #: 95809-78-2
Chemical Name: 6,8-bis(benzylthio)octanoic acid
SMILES Code: O=C(O)CCCCC(SCC1=CC=CC=C1)CCSCC2=CC=CC=C2
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
In vitro activity:In vitro, CPI-613 produces the selective toxicity against several tumor cell lines including H460 human lung cancer cells and Saos-2 human sarcoma cells with EC50 of 120 μM and 120 μM, respectively. CPI-613 disrupts H460 cancer cell mitochondrial metabolism including inhibition of PDH complex activity and loss of mitochondrial membrane potential in a time- and drug dose-dependent fashion. In addition, CPI-613 (240 μM) also induces both apoptotic and non-apoptotic cell death in H460 human lung cancer and Saos-2 human sarcoma cells.
Cell Assay: Devimistat (CPI-613) is a lipoic acid analog that inhibits pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase, disrupts mitochondrial metabolism and shows strong antitumor activity.
Lot#: V085301,Purity ≥98%
COA
MSDS
NMR
HPLC
Lot#: V085302,Purity ≥98%